pentobarbital will reduce the extent or effect of cobimetinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Stay clear of coadministration. Solid or average CYP3A inducers may well minimize cobimetinib systemic exposure by >eighty% and lower its efficacy.pentobarbital will minimize the level or impact of buspirone by af